Bernstein lowered the firm’s price target on Centene (CNC) to $36 from $40 and keeps an Outperform rating on the shares. The firm sees a sector turnaround in the government MCO sector beginning in 2026, but expects to see bumps in the recovery. Bernstein believes all MCO sectors present attractive entry points, with MA likely to see the nearest term earnings improvements and Medicaid representing the most attractive valuations.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC:
- Unusually active option classes on open September 4th
- Centene price target lowered to $33 from $45 at Barclays
- Centene call volume above normal and directionally bullish
- ACA Rule Pause Offers Relief to UnitedHealth (UNH) and Peers Facing Rising Costs
- CNC Lawsuit Alert! Class Action Lawsuit Against Centene Corporation